Alimera Sciences (NASDAQ:ALIM) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research report released on Saturday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other research firms also recently issued reports on ALIM. HC Wainwright restated a buy rating and set a $9.00 price objective on shares of Alimera Sciences in a report on Thursday. Alliance Global Partners cut Alimera Sciences from a buy rating to a neutral rating and lowered their target price for the company from $11.00 to $4.50 in a research note on Monday, November 21st.

Alimera Sciences Trading Down 5.3 %

NASDAQ ALIM opened at $2.26 on Friday. The stock’s 50-day moving average price is $2.58 and its two-hundred day moving average price is $4.36. The company has a market cap of $15.79 million, a PE ratio of -0.85 and a beta of 1.34. Alimera Sciences has a 1 year low of $2.03 and a 1 year high of $7.92.

Hedge Funds Weigh In On Alimera Sciences

Several institutional investors and hedge funds have recently bought and sold shares of ALIM. Caligan Partners LP purchased a new position in Alimera Sciences during the 4th quarter valued at about $1,297,000. Susquehanna International Group LLP bought a new stake in shares of Alimera Sciences in the 4th quarter valued at approximately $92,000. Millennium Management LLC bought a new stake in shares of Alimera Sciences in the 4th quarter valued at approximately $32,000. Finally, Renaissance Technologies LLC grew its stake in shares of Alimera Sciences by 2.3% in the 2nd quarter. Renaissance Technologies LLC now owns 127,693 shares of the biopharmaceutical company’s stock valued at $698,000 after buying an additional 2,900 shares in the last quarter. Hedge funds and other institutional investors own 24.58% of the company’s stock.

About Alimera Sciences

(Get Rating)

Alimera Sciences, Inc engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion.